Table 4. Strength of Treatment Effects in Three Groups of Intervention.
| µ1 | µ2 | SD | Effect Size | |
| Pioglitazone | ||||
| Weight, kg | 76.95 | 77.82 | 9.25 | - 0.09 |
| BMI a, kg/m2 | 27.36 | 27.67 | 1.68 | - 0.18 |
| FBS a, mmol/L | 95.45 | 84.91 | 6.07 | 1.74 |
| TG a, mg/dL | 252.18 | 224.09 | 49.94 | 0.56 |
| CHOL a, mg/dL | 195.68 | 178.64 | 33.15 | 0.51 |
| AST a, IU/L | 55.09 | 37.59 | 9.08 | 1.93 |
| ALT a, IU/L | 77.45 | 52.27 | 16.53 | 1.52 |
| Insulin Levels, mmol/L | 14.20 | 11.76 | 3.52 | 0.69 |
| HOMA-IR a | 2.89 | 2.12 | 0.80 | 0.95 |
| Metformin | ||||
| Weight, kg | 76.91 | 75.46 | 9.71 | 0.15 |
| BMI, kg/m2 | 27.53 | 27.00 | 1.91 | 0.28 |
| FBS, mmol/L | 95.09 | 87.41 | 6.14 | 1.25 |
| TG, mg/dL | 248.36 | 222.73 | 51.79 | 0.49 |
| CHOL, mg/dL | 193.00 | 175.86 | 33.40 | 0.51 |
| AST, IU/L | 54.86 | 42.50 | 10.65 | 1.16 |
| ALT, IU/L | 78.36 | 60.95 | 17.04 | 1.02 |
| Insulin Levels, mmol/L | 14.17 | 12.06 | 3.78 | 0.56 |
| HOMA-IR | 2.87 | 2.24 | 0.87 | 0.72 |
| Silymarin | ||||
| Weight, kg | 77.00 | 77.09 | 9.51 | - 0.01 |
| BMI, kg/m2 | 27.44 | 27.48 | 1.67 | - 0.02 |
| FBS, mmol/L | 95.95 | 93.95 | 5.93 | 0.34 |
| TG, mg/dL | 254.18 | 239.09 | 54.38 | 0.28 |
| CHOL, mg/dL | 191.68 | 181.32 | 33.12 | 0.31 |
| AST, IU/L | 56.00 | 37.77 | 9.92 | 1.84 |
| ALT, IU/L | 78.73 | 53.05 | 16.85 | 1.52 |
| Insulin Levels, mmol/L | 14.19 | 13.50 | 3.76 | 0.18 |
| HOMA-IR | 2.90 | 2.70 | 0.89 | 0.22 |
aAbbreviations: ALT, alanineaminotransferase; AST, aspartate aminotransferase;BMI, body mass index; CHOL, cholesterol; FBS, fasting blood sugar;HOMA-IR, homeostasis model assessment index for insulin resistance; TG,triglyceride.